Reply to: Fibromyalgia and hyperlipidemia: a balance between cardiovascular risk reduction and muscular side effects

Sir,

We wish to extend our appreciation for the thoughtful letter by Sbrana and Dal Pino (1) in response to our article (2), which delves into the multifaceted realm of the management of fibromyalgia (FM) patients with concurrent hyperlipidemia. First and foremost, we certainly appreciate their observation regarding the heightened necessity for FM patients to manage hyperlipidemia and other associated cardiovascular comorbidities (1). These comorbidi- ties may often arise due to the pronounced overlap between FM and obesity, which, as corroborated by Atzeni et al. (3), can exacerbate FM severity. This substantiates the imperative of a comprehensive approach that considers both the cardiovascular and musculoskeletal aspects of patient care. The intricacies of the relationship between lipid-lowering therapies (LLT), among which statins, and FM or FM-like symptoms are indeed worthy of attention. As highlighted by Sbrana and Dal Pino, a substantial proportion of FM patients in their cohort exhibit poor adherence to LLT due to musculoskeletal symptoms, but just some of them can be attributed to statins (1). As emerging evidence suggests, the association between statins and muscle symptoms may not be as significant, whether patients have FM or not (4-6). This underscores the need to carefully evaluate the benefit-risk profile of statin therapy and LLT in general on an individual basis, taking into account the potential for the nocebo effect. Specifically, there is relevance of the nocebo effect in statin-associated muscle symptoms (SAMS), as discussed in the paper by Pedro-Botet et al. (7). This study brings to light the importance of considering the psychosocial dimensions of treatment in the context of SAMS. Notably, patients who reported SAMS experienced subjective symptom alleviation and objective improvements in muscle function following statin withdrawal (8). Furthermore, the susceptibility of FM patients to the nocebo effect accentuates the necessity of patient education, shared decision-making, and a patient-centred approach when contemplating treatment options, including LLT (9).

It is also paramount to underscore the significance of non-pharmacological approaches in FM management. This recommendation aligns with the EULAR guidelines for FM management (10) and holds promise, not only for FM symptoms but also for those contending with mild hyperlipidaemia and cardiovascular risk factors, including obesity (11). The potential benefits of lifestyle interventions, such as diet and exercise, for both FM and hyperlipidaemia, substantiates the value of a more comprehensive patient care approach. Finally, the recognition of the importance of personalised lipid-lowering therapy, particularly for FM patients who may be susceptible to muscular symptoms with traditional statins, is apt. The advent of newer lipid-lowering drugs offers a compelling alternative with reduced impact on muscular symptoms, as Sbrana and Dal Pino inferred in their letter (1).

In conclusion, the management of hyperlipidaemia in FM patients is a multifaceted endeavour that warrants a comprehensive strategy. Personalised care, incorporating non-pharmacological interventions and newer lipid-lowering agents, holds the potential to enhance therapeutic adherence while effectively addressing the distinctive needs of FM patients.

V. GIORGI, MD
P. SARZI PUTTINI, MD
‘Rheumatology Department, IRCCS Galeazzi-Sant’Ambrogio Hospital, Milan, Italy.
Please address correspondence to: Valeria Giorgi, Rheumatology Department, IRCCS Galeazzi-Sant’Ambrogio Hospital, Via Cristina Belgioioso 173, 20161 Milan, Italy.
E-mail: vale.gio@fastwebnet.it
Competing interests: none declared.

References